Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC HF 25: SCD-PROTECT
Author(s): Johann Bauersachs Added: 11 months ago
ESC HF 25 - SCD-PROTECT zeigt hohes Risiko für plötzlichen Herzstillstand (SCA) und plötzlichen Herztod (SCD) während der frühen medikamentösen Therapieoptimierung bei reduzierter LVEF bei Patienten mit neu diagnostizierter nicht-ischämischer Kardiomyopathie oder MI/KHK.Prof Johann Bauersachs (Medizinische Hochschule Hannover, Hannover, DE) diskutiert Ergebnisse aus dem SCD-PROTECT studie, einer… View more

MI/ACS

Heart Failure
Molecular Mechanisms of the Failing Heart: A Fatal Regression?
Author(s): Manami Katoh , Jin Komuro , Shunsuke Inoue , et al Added: 1 year ago

Heart Failure
HFA 24: FINE-HEART: Design & Baseline Characteristics
Author(s): Muthiah Vaduganathan Added: 1 year ago
HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the design and baseline characteristics of the FINE-HEART(Bayer) integrated pooled analysis of finerenone, an on-steroidal mineralocorticoid receptor (MRA) antagonist, in over 19000 patients with heart failure and CKD.FINE-HEART includes patients with type 2 diabetes, chronic kidney disease and/or… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Prevention: What's New at HFA 2025?
Author(s): Harriette Van Spall , Maja Cikes Added: 10 months ago
ESC HF 25 - Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Maja Cikes (University Hospital Centre Zagreb, HR) for an insightful wrap up of the novel data concerning preventive cardiology that was presented at 2025's Heart Failure Congress.Trials discussed include:REDICAE (00:42)FINEARTS HF (02:27)CRISPR Gene Editing with Nexiguran Ziclumeran (05:53)HELIOS B (07:12)RESHAPE… View more

Heart Failure
Pharmacological Therapy of HFrEF in 2025
Author(s): Massimo Mapelli , Filippo Maria Rubbo , Simona Costantino , et al Added: 8 months ago

Heart Failure
Inside the Data: Prof. Donal on the Tri.Fr Extended Follow-up Results
Author(s): Erwan Donal Added: 2 weeks ago
ACC 2026 - Two randomised trials position TriClip TEER as a transformative option in TR, delivering significant reductions in heart failure hospitalisations and supporting earlier intervention in clinical practice.Prof Erwan Donal (Hospital Pontchaillou of Rennes, Rennes, FR) joins us on-site at ACC 2026 to share the findings from two randomised trials (Tri.Fr and TRILUMINATE Pivotal)… View more

Intervention

Heart Failure
Novi Yanti Sari
Job title: Heart Failure Cardiologist
Dr Novi Yanti Sari is a heart failure cardiologist from Indonesia. She graduated from the National Cardiovascular Center Harapan Kita–Faculty of Medicine, University of Indonesia, then pursued a fellowship in advanced HF at the National University Heart Centre Singapore. She pioneered the first heart failure and cardio-oncology pr gram in South Sumatra, Indonesia, and now leads both programs at… View more
HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie
Author(s): Harriette Van Spall , Mark Petrie Added: 1 year ago
HFA 2024 — Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Mark Petrie (University of Glasgow, UK) for an insightful wrap up of the novel data presented at 2024's Heart Failure Congress.00:24 - STEP HFpEF Programme: Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF & Semaglutide therapy and diuretic use in obesity-related HFpEF02:20 - EMPACT-MI: The effect of… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
ESC 25: The VICTOR & VICTORIA Pooled Analysis
Author(s): Javed Butler Added: 7 months ago
ESC Congress 2025 - Vericiguat significantly reduced risks of CV mortality and HF hospitalisations, as well as all-cause mortality across both the VICTOR and VICTORIA Trial.Dr JavedButler (Baylor Scott & White Health, Dallas, US) joins us to discuss findings from a pooled analysis of the recent VICTOR and VICTORIA trials, with data from 11155 participants with heart failure with reduced ejection… View more

Heart Failure
Heart Rate Lowering Benefits are Context-Dependent, Meta-Analysis Finds
Added: 9 months ago Source:  Radcliffe Cardiology
AUTHOR: Jennifer ThomasThe long-standing debate over the benefits of heart rate (HR)-lowering drug treatment, particularly in patients with hypertension, has been addressed in a new large-scale meta-analysis. The findings, published in the European Heart Journal, suggest that the advantages of reducing HR are highly dependent on the patient's underlying clinical condition, with significant… View more

MI/ACS

Prevention & Chronic Conditions